- Industry: Biotechs
- Founded: 1992
- Country: United States
- CEO: Leonard Bell
- Website: www.alexionpharm.com
- Employees: 1,373
- Sales: $1.13 B
- Headquarters: Cheshire, Connecticut
Profile
Alexion Pharmaceuticals, Inc. (Alexion) is a
biopharmaceutical company focused on serving patients with severe and
ultra-rare disorders through the development and commercialization of
life-transforming therapeutic products. Its marketed product Soliris
(eculizumab) is the first and only therapeutic approved for patients
with two ultra-rare and severe disorders resulting from chronic
uncontrolled activation of
the complement component of the immune system: paroxysmal nocturnal
hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder,
and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and
life-threatening genetic disease. On February 7, 2012, it acquired
Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents
and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28,
2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired
Asfotase alfa in February 2012.